These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 18285440)

  • 1. Practical issues arising in an exploratory analysis evaluating progression-free survival as a surrogate endpoint for overall survival in advanced colorectal cancer.
    Hughes MD
    Stat Methods Med Res; 2008 Oct; 17(5):487-95. PubMed ID: 18285440
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Individual- and trial-level surrogacy in colorectal cancer.
    Buyse M; Burzykowski T; Michiels S; Carroll K
    Stat Methods Med Res; 2008 Oct; 17(5):467-75. PubMed ID: 18285439
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Surrogate endpoints for overall survival in advanced colorectal cancer: a clinician's perspective.
    Piedbois P; Miller Croswell J
    Stat Methods Med Res; 2008 Oct; 17(5):519-27. PubMed ID: 18285441
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Surrogate end points for median overall survival in metastatic colorectal cancer: literature-based analysis from 39 randomized controlled trials of first-line chemotherapy.
    Tang PA; Bentzen SM; Chen EX; Siu LL
    J Clin Oncol; 2007 Oct; 25(29):4562-8. PubMed ID: 17876010
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Two simple approaches for validating a binary surrogate endpoint using data from multiple trials.
    Baker SG
    Stat Methods Med Res; 2008 Oct; 17(5):505-14. PubMed ID: 18285436
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A simple meta-analytic approach for using a binary surrogate endpoint to predict the effect of intervention on true endpoint.
    Baker SG
    Biostatistics; 2006 Jan; 7(1):58-70. PubMed ID: 15972889
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of progression-free survival as a surrogate marker in oncology trials: some regulatory issues.
    Chakravarty A; Sridhara R
    Stat Methods Med Res; 2008 Oct; 17(5):515-8. PubMed ID: 18285437
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of meta-analysis for the validation of surrogate endpoints and biomarkers in cancer trials.
    Buyse M
    Cancer J; 2009; 15(5):421-5. PubMed ID: 19826362
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of tumor response, disease control, progression-free survival, and time to progression as potential surrogate end points in metastatic breast cancer.
    Burzykowski T; Buyse M; Piccart-Gebhart MJ; Sledge G; Carmichael J; Lück HJ; Mackey JR; Nabholtz JM; Paridaens R; Biganzoli L; Jassem J; Bontenbal M; Bonneterre J; Chan S; Basaran GA; Therasse P
    J Clin Oncol; 2008 Apr; 26(12):1987-92. PubMed ID: 18421050
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Surrogate endpoint validation: statistical elegance versus clinical relevance.
    Green E; Yothers G; Sargent DJ
    Stat Methods Med Res; 2008 Oct; 17(5):477-86. PubMed ID: 18285438
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Surrogate endpoints for overall survival in early colorectal cancer from the clinician's perspective.
    Grothey A
    Stat Methods Med Res; 2008 Oct; 17(5):529-35. PubMed ID: 18285442
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Biomarker-Surrogacy Evaluation Schema: a review of the biomarker-surrogate literature and a proposal for a criterion-based, quantitative, multidimensional hierarchical levels of evidence schema for evaluating the status of biomarkers as surrogate endpoints.
    Lassere MN
    Stat Methods Med Res; 2008 Jun; 17(3):303-40. PubMed ID: 17925313
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design and endpoints of clinical trials in hepatocellular carcinoma.
    Llovet JM; Di Bisceglie AM; Bruix J; Kramer BS; Lencioni R; Zhu AX; Sherman M; Schwartz M; Lotze M; Talwalkar J; Gores GJ;
    J Natl Cancer Inst; 2008 May; 100(10):698-711. PubMed ID: 18477802
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Does the Prentice criterion validate surrogate endpoints?
    Berger VW
    Stat Med; 2004 May; 23(10):1571-8. PubMed ID: 15122737
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of progression-free survival in oncology trials: some common statistical issues.
    Carroll KJ
    Pharm Stat; 2007; 6(2):99-113. PubMed ID: 17243095
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Validation of surrogate endpoints in digestive oncology].
    Methy N; Bedenne L; Bonnetain F
    Bull Cancer; 2009 May; 96(5):591-5. PubMed ID: 19423485
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Endpoints and surrogate endpoints in colorectal cancer: a review of recent developments.
    Piedbois P; Buyse M
    Curr Opin Oncol; 2008 Jul; 20(4):466-71. PubMed ID: 18525345
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Statistical evaluation of biomarkers as surrogate endpoints: a literature review.
    Weir CJ; Walley RJ
    Stat Med; 2006 Jan; 25(2):183-203. PubMed ID: 16252272
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessing surrogacy from the joint modelling of multivariate longitudinal data and survival: application to clinical trial data on chronic lymphocytic leukaemia.
    Deslandes E; Chevret S
    Stat Med; 2007 Dec; 26(30):5411-21. PubMed ID: 18058850
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of cancer drugs on survival: often poorly evaluated.
    Prescrire Int; 2009 Aug; 18(102):180-3. PubMed ID: 19746577
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.